Sandra Hodge

Professor Sandra Hodge

Head Chronic Lung Disease Research Lab

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Prof Sandra Hodge is a University of Adelaide Research Fellow and Director of Chronic Inflammatory Lung Disease Research at the Royal Adelaide Hospital and University of Adelaide. Her lab was the first to describe a failed phagocytic capacity of lung macrophages with pro-inflammatory consequences in severe, treatment refractory chronic lung diseases including COPD, cystic fibrosis and severe asthma, and in response to cigarette smoke, bushfire smoke and E-cigarette vapour. The team focus then shifted to identifying and trialing new macrophage-targeted therapies.
She has published >150-refereed manuscripts, and collaborates with industry and leading research groups across Australia and internationally. International invitations include as Drug Discovery meeting panelist, industry advisor, and member of conference-organizing committees, invited speaker and session chair. She is currently CI on The Australasian COVID-19 Trial (ASCOT), a randomised control trial that will initially test two treatments for hospitalised COVID-19 patients.
Participation in major health policy advisory groups include as TSANZ Board Director, Treasurer, and Research Committee Chair. She was awarded the title of Fellow of the Thoracic Society of Australia and New Zealand (FThorSoc).
Policy advisory roles include TSANZ Position Paper writing groups, presentation to the SA Government Select Enquiry into E-cigarettes and contribution to TSANZ’s submission to the Australian Government’s inquiry into the Use and Marketing of E-Cigarettes in Australia.
She has received ~$16 mill in competitive research funding ($11.5 mill in the last 10 years, and $8 mill as CIA).

 

Chronic Inflammatory Lung Disease Research Lab

Image removed.Our Team

We are part of the Lung Research Unit, at the Department of Thoracic Medicine at the Royal Adelaide Hospital and The University of Adelaide. Our research program largely focusses on macrophage-targeted therapeutic approaches for severe chronic lung diseases that are resistant to current therapies.

Funded collaborative projects include those in (COPD/emphysema), lung transplant rejection, steroid-resistant asthma and bronchiectasis in Indigenous children. Our multi-discipline and internationally recognised team was the first to describe failed clearance of apoptotic cells by airway macrophages (efferocytosis) in COPD that underlies the chronic inflammation and tissue damage and is not resolved with cessation of cigarette smoking once the disease is established.

We have already shown, in human clinical studies and/or murine models that several macrophage-targeted therapies including macrolide antibiotics have properties that restore airway function in this context, beyond combatting microbial infection.  In a recent large randomised controlled clinical trial of the macrolide antibiotic Azithromycin (published in Thorax 2017) we and our national collaborators identified Azithromycin as a useful add-on therapy in persistent severe symptomatic asthma. However, bacterial resistance following long-term macrolide treatment necessitates new approaches, and we are now investigating new macrolides, which lack antibiotic but retain anti-inflammatory properties (in collaboration with Gilead Sciences, USA). We have recently published exciting proof-of-concept findings in the Am J Physiol.

Sandra HODGE, MSc, PhD, FThorSoc: Brief Track Record

Top manuscripts last 10yrs: All below are Q1 rated and in top 10 journals in field.

1. Landmark RCT (AMAZES) showing Azithromycin reduces asthma exacerbations by >30% over 1yr. Incorporated into latest GINA severe asthma guidelines with major implications for changes in practice. Lancet 2017, FWCI 28, PMID28687413, highly cited Q1 paper

2. New knowledge of mechanisms for colonisation of potentially pathogenic bacteria and its severe clinical manifestations in COPD, and a rationale for use of long-term Azithromycin to reduce colonisation and prevent exacerbations, Respirology 2012 PMID22288725, Featured in MDLinx and Lung Disease News, Editorial focus (Hansbro and Jarnicki), FWCI 39, in the top 25% of all research outputs scored by Altmetric Media.

3. Pioneering study with Gilead US showed that new non anti-microbial macrolides are anti-inflammatory and improve macrophage function. This approach provides an alternative to macrolides thus addresses significant concerns about anti-microbial resistance. A resultant change in drug development focus by the pharmaceutical company has progressed to pre-clinical murine studies. Am J Physiol 2017 PMID28258107

4. One of several cigarette smoke-exposed murine studies showing anti-inflammatory effects of new macrophage-targeted therapies provided mechanistic knowledge and advised a great deal of subsequent research by us and others (eg, macrolides). Am J Respir Cell Mol Biol 2011, PMID20595463 Faculty 1000 selected, FWCI 4.31

5. One of 5 from 5yr prospective cohort study that identified potential development of bronchiectasis in children with PBB, a common cause of childhood chronic cough. Incorporated into ERS taskforce paper and reviews, informing future therapy and the need for better clinical follow up of children with PBB. Chest 2016 PMID26867834.

Grants and awards: My salary, and those of my team have been 100% funded by competitive grants (>$13 million as CI), including grants from NHMRC (9 as CI), specialist agencies (Asthma Australia, ARC, Cancer Council, CellCept, TSANZ/Allan Hanbury’s, TSANZ Robert Pierce GIA for Indigenous Lung Health, ALF/Boehringer Ingelheim, Ch7 CRE, Brine Bequest, and state competitive schemes. I was awarded the Hanson Institute Early Career Researcher of the Year and the prestigious University of Adelaide Beacon Research Fellowship.

Peer Recognition: National standing is evident by appointment to NHMRC GRPs (2012-2019); GRP Co-Chair (2013), Deputy Convenor (2013-2014) and Convenor (2015-2016) of  TSANZ Cell Biology and Immunology SIG, member TSANZ Education and Research Sub-committee (2012-16), Co-chair Research Sub-committee (2017-2018) and Chair (current) and invitations to chair numerous oral sessions including the Ann Woolcock YIA over several years. In 2012 I was awarded a TSANZ Silver Pin for service to the Society; in 2020 awarded a gold pin, and in 2019 appointed as a Fellow of the Society (FThorSoc). I am elected TSANZ Board Director and have served as Treasurer and member Finance and Risk Assessment Committee. I was National President of the AFCG, represented NHMRC at Science Meets Parliament, invited to the TEVA Respiratory Summit, and Australian Mucosal Immunology Group. I am current member of Registries and Clinical Trials sub-committee; Rebecca Cooper Scientific Advisory Committee; RAH Clinical Project Grant, RIBG and Research Equipment Advisory committees. I am a member and have been involved as conference organiser, speaker and Chair for 8 international societies including ATS, ISHLT, APSR/ACCP, AFCG/ASI/HLDA and numerous national societies.

Reviewing roles: 15 international; >30 national bodies/yr; NHMRC GRP 2012-19; PhD examiner 5 Aust Universities; 43 journals eg Lancet, NEJM, all top respiratory journals, invited guest-editor 5 special issues, Chief Book Editor, Editorial Board Member 3 scientific journals (currently Inflammation Research); Chair TSANZ Research Committee- objective to advise the Board on strategies for supporting research amongst members, and providing unbiased adjudication of >$1mill/year in awards.

Community: 4 clinical trials, impacting clinical practice; career advisory forums for 2ndry students as a founding member of Zonta Club; work experience for ~4/year 2ndry and 3rd year Biomedical Science students; represented NHMRC at ‘Science Meets Parliament’ raising awareness of COPD among parliamentarians; media releases (24 since 2012) and feature in ‘The Limbic’, Spanish ‘Muy Interesante’ and Boehringer booklet ‘Where are they now?’ as one of 12 top Australian researchers in my field raised community awareness of my research.

Membership of major health policy advisory groups and translation into policy / practice

As TSANZ Board Director contributed to five position papers, three guidelines; two current position paper writing groups and submission to 2018 Federal Government Inquiry into E-cigarettes; consulted by Government as witness for the 2017 SA Government Select Inquiry into E-cigarettes (resultant changes to legislation); contributed to 2012 Lung Health Alliance Submission for Strategic Review of Health and Medical Research; invited Pharmaceutical Company Advisor (GlaxoSmithKline R&D 2006; AstraZeneca R&D Sweden 2015). Clinical trial involvement including two with azithromycin in COPD and asthma advised better-informed use of add-on macrolide therapies in chronic lung diseases and likely incorporation into International clinical guidelines. With Gilead USA our current investigations of non-antimicrobial macrolides are addressing the global priority of halting the generation of further antibiotic resistant bacteria.

International collaborations/ interactions with pharmaceuticals companies: My expertise and models of COPD and other chronic inflammatory lung are now internationally sought after and several of our discoveries have been the subject of national electronic and print media news. Collaborations include Aust. Red Cross Blood Service, AstraZeneca R&D, Advisor (2011-2012), GlaxoSmithkline (USA) COPD Drug Discovery group; (2008), Universities of Duisburg-Essen Germany, Tabuk, Saudi Arabia and Gothenburg Sweden, National Research Institute on Food & Nutrition Italy, Imperial College London, Gilead Sciences USA, Universitätsmedizin Berlin and amilitary Hospital 175, Vietnam.

Selected invitations to speak at major international conferences (*fully funded):

  • 2019 Combined Respiratory Society of Vietnam and University of Medical Sciences, Ho Chi Minh City (Symposium Plenary speaker)*.
  • 2018 Le Centre Hospitalier Universitaire Vaudois Switzerland (Invited speaker).
  • 2018 Asthma and Respiratory Foundation New Zealand (Plenary 1. Keynote speaker)*.
  •  2018 Asthma and Respiratory Foundation New Zealand (Plenary 2. Panel member)*.
  • 2015 Amgen USA (Invited speaker).
  • 2014 Université de Lausanne, Switzerland (Symposium Plenary speaker).
  • 2013 Le Centre Hospitalier Universitaire Vaudois Switzerland (Plenary speaker).
  • 2011 Int Lectin Society (Symposium keynote speaker) *.
  • 2010 American Thoracic Society (ATS) (Symposium keynote speaker*).
  • 2009 National Jewish Medical Research, Denver, USA* (Visiting Professor and plenary speaker).
  • 2009 University of Denver, USA* (Symposium Plenary speaker).
  • 2008 GlaxoSmithkline (USA) COPD Drug Discovery group* (Panel member).
  • 2010 ATS New Orleans 2010 Oral Cell Biology Session, (Panel member).
  • 2007 12th Congress of APSR/2nd Joint Congress of the APSR/ACCP, Australia (Invited speaker).
  • 2004 Federation of Immunological Societies of Asia-Oceania (FIMSA) (Workshop facilitator).

 

Current research programs include:

  • Macrophage-targeted therapies in chronic inflammatory lung diseases

  • LC3-associated phagocytosis: common target in COPD and cancer pathogenesis

  • Sphingosine-1 phosphate signalling  – novel mediator of vascular dysfunction in children with cystic fibrosis

  • Zinc influx regulates autophagy and pro-constrictive changes in microvascular cells

  • Pulmonary hypertension and its therapeutic targeting in cystic fibrosis

  • Role of endothelin-1 signalling by neutrophils in cystic fibrosis-associated pulmonary hypertension

  • Multiple inflammasome activation in chronic lung diseases

  • Ex vivo models of accelerated cell aging in translation to senotherapy in COPD

  • Role of LC3-associated phagocytosis in tumour reccurrence following cytotoxic anti-tumour treatment

  • Research funding acknowledgements

The National Health and Medical Research Council, Thoracic Society of Australia and New Zealand, Lung Foundation Australia, Royal Adelaide Hospital, Channel 7 Children’s Research Foundation, Cystic Fibrosis Foundation, and the University of Adelaide.

 

    Expand
  • Appointments

    Date Position Institution name
    2020 - 2020 Professorial Research Fellow The University of Adelaide
    2017 - 2019 Beacon Professorial Research Fellow The University of Adelaide
    2010 Head Chronic Inflammatory Lung Disease Research Lab Royal Adelaide Hospital, Adelaide
  • Awards and Achievements

    Date Type Title Institution Name Country Amount
    2018 Distinction Treasurer, Thoracic Society of Australia and New Zealand Treasurer, Thoracic Society of Australia and New Zealand Australia
    2018 Invitation Writing Group Member: TSANZ Position Paper: Electronic Nicotine (and non-nicotine) Delivery Systems TSANZ Position Paper: Electronic Nicotine (and non-nicotine) Delivery Systems Australia
    2018 Invitation Writing Group Member: TSANZ Position Paper Alpha-1 Antitrypsin deficiency writing group TSANZ Australia
    2018 Nomination NHMRC Grant Review Panel NHMRC Australia
    2018 Invitation Chair and Judge, Anne Woolcock New Investigator Award Thoracic Society of Australia and New Zealand Australia
    2017 Award International Travel Award TSANZ/Menarini Australia 3,000
    2017 Invitation Grand Round Presentation Royal Adelaide Hospital Australia
    2017 Invitation Keynote speaker Thoracic Society of Australia and New Zealand Australia
    2017 Award COPD Research Award Boehringer Ingelheim/ TSANZ Australia
    2017 Award University Professorial Research Fellow (E) The University of Adelaide Australia
    2017 Distinction Co-Chair Research Sub-Committee Thoracic Society of Australia and New Zealand Australia
    2017 Invitation Invoited Chair, International Meeting Asia Pacific Society for Respirology Australia
    2017 Award International Research Travel Award Lung Foundation Australia/ A. Menarini Australia Australia
    2017 Invitation Invited presenter, SA Government Select Enquiry into E-cigarettes SA Government Australia
    2017 Invitation Judge, TSANZ 50th Anniversary Benevolent Grant Thoracic Society of Australia and New Zealand Australia
    2017 Invitation Invited Grand Round Presenter, Royal Adelaide Hospital Royal Adelaide Hospital Australia
    2017 Invitation Contributer, TSANZ submission to Australian Government Inquiry into the Use and Marketing of Electronic Cigarettes and Personal Vaporisers in Australia Australian Federal Government Australia
    2016 Award TSANZ/Robert Pierce Award for Indigenous Lung Health Research
    2014 Achievement Expert Guide Australia: Expert in Medicine/ Medical Research Category Asthma
    2013 Award TSANZ/Robert Pierce Award for Indigenous Lung Health Research
    2012 Award TSANZ Award of Silver Pin for service to the Society
  • Education

    Date Institution name Country Title
    The University of Adelaide Australia PhD
    University of South Australia Australia MSc
    University of South Australia Australia Diploma in Applied and Visual Art
    University of South Australia Australia Diploma in Biomedical Science
  • Postgraduate Training

    Date Title Institution Country
    2020 Finance for the Non Financial Manager University of Sydney Australia
  • Research Interests

Grants & Funding

Total funding for career $15,980,192  [$750,500.00 relinquished]

Current Funding: NHMRC
2018-2021 NHMRC PROJECT GRANT Role for zinc and ZIP2 in the action of nitric oxide and in vascular protection against cigarette smoke and cardiovascular disease. Zalewski P, Hodge S, Beltrame J, Murgia C, Tavella R. $660,940.60
2013-2016 NHMRC CAREER DEVELOPMENT FELLOWSHIP R.D. Wright Biomedical CDF Level 2 APP1045511        Investigating the causes of failed efferocytosis in COPD/emphysema with a view to identifying novel therapeutic targets. Hodge S    $439,920
2016-2018 NHMRC PROJECT GRANT Exploiting increased autophagy in bronchial epithelial cells: a new therapeutic approach for chronic obstructive pulmonary disease (COPD). Hodge S, Zalewski P, Roscioli E. $724,161
2016-2018 NHMRC PROJECT GRANT Targeting the defective airway macrophage function in chronic obstructive pulmonary disease (COPD): a new therapeutic approach. Hodge S, Reynolds PN. $710,928
2016- NHRMC PROJECT GRANT Conquering the final frontier in lung transplantation - Mesenchymal stromal cell therapy for chronic lung allograft dysfunction. Chambers D, Hopkins P, Glanville A, Westall G, Holmes M. Hodge S (AI) $1,887,790.
2014-2018 NHMRC CRE APP1058550 Phenotyping severe asthma for improved outcomes: a translational CRE. Gibson, Marks, McDonald, Wark, Upham, Thien, James, Reddell, King, Smith, Hodge S (AI) $2,499,750
2013-2016 NHMRC Project Grant 1042601 Protracted bacterial bronchitis: long term outcomes, systemic and airway predictors of recurrence   Chang A, Upham J, Gibson P, Yerkovich S, Baines K, Hodge S, Pizzutto S, Masters I, Buntain H. $777,376.76

                               

Current funding- non-NHMRC
2021-2022 CF Foundatiopn Hypoxia and Vascular dysfunction in cystic fibrosis. Hodge S $50,000
2020-2021 WCH Foundation Research Grant. Hypoxia and Vascular dysfunction in cystic fibrosis. Hodge S, $100,000
2020-2021 Thoracic Society of Australia and New Zealand/ Vertex Adult Cystic Fibrosis Research Award Hodge S $75,000
2017-2019 The University of Adelaide Beacon Research Fellowship Hodge S $574,689
2018 Royal Adelaide Hospital Near Miss Funding Hodge S $50,000
2018 RAH Respiratory Clinical Trials Unit Support for Transplant Research Hodge G and Hodge S $35,000
2017-2019 Research Infrastructure Block Grants (RIBG)   Hodge S $70,000
2017 RAH Respiratory Clinical Trials Unit Support for Transplant Research Hodge G and Hodge S $30,859
2017 RAH Clinical Project Grant Whittall J, Hodge S $50,000
2017 Thoracic Society of Australia and New Zealand Rob Pierce Grant for Indigenous Health Research Hodge S $50,000
2017 Thoracic Society of Australia and New Zealand / Boehringer COPD Research Award Hodge S and Hodge G $30,000
2017 Lung Foundation Australia/ A. Menarini Australia Pty. Ltd. International Travel Grant Hodge S $50,000
2017 Adelaide medical school investment for success near miss funding Zalewski P, Hodge S $30,000
2016 Channel 7 Children’s Research Foundation   Hodge S, Chang A, Upham J $75,000
2013-2019 Royal Adelaide Hospital CCF Brine Bequest Mannose binding lectin as a novel therapy to prevent COPD/emphysema in smokers. Hodge S $300,000
2016 TSANZ and National Asthma Council Australia Are e-cigarettes as harmless as sellers would have you believe? Investigating the effect of Vaping on macrophage function. Ween M, Hodge S $60,000
2016-2017 Astra Zeneca/ Thoracic Society of Australia and New Zealand Respiratory Research fellowship Roscioli E, Hodge S (Supervisor) $150000
2016 RAH Clinical Project Grant The role of autophagy in airway epithelial cells exposed to bush fire smoke Roscioli E, Hodge S, Jersmann H.  $50,000
2016 RAH Clinical Project Grant Are e-cigarettes as harmless as sellers would have you believe? Investigating the effect of Vaping on macrophage function. Ween M, Hodge S.   $50,000
2016 Asthma Australia Travel Award for mid-career researchers   Tran H, Hodge S (supervisor) $5000
2016 RIBG Funding   Hodge S. $70,000
2016 RIBG Funding   Hodge G, Hodge S $22,000

Previous funding: NHMRC

2013-2015 National Health and Medical Research Council of Australia Project Grant 1045514   Identification and therapeutic modulation of sphingolipids as novel lung macrophage-targeted treatments for COPD/emphysema     Hodge S, Haberberger R, Reynolds PN, Meech R.     $670,475.81
2010-2012 National Health and Medical Research Council of Australia Project Grant 627223 Alveolar macrophage zinc and zinc transporters and their role in phagocytosis  Zalewski P, Hodge S, Jersmann H. $284,044.00
2010-2012 National Health and Medical Research Council of Australia Project Grant 626972      Modulation of macrophage function as a therapy for chronic obstructive pulmonary disease (COPD)     Hodge S, Reynolds P, Holmes M, Hodge G, Jersmann J.      $428,104.00
2009-2013 National Health and Medical Research Council of Australia Project Grant 569246    Asthma Macrolides Azithromycin Efficacy and Safety study.  PG Gibson, JL Simpson, J Upham, PR Reynolds, IA Yang, S Hodge,  AL James.    $3,098,136.00
2009-2011   National Health and Medical Research Council of Australia Project Grant 565210    Surfactant protein D as a candidate therapy in COPD.  P Reynolds, S Hodge, H Clark.   $400,394.00
2008-2011 National Health and Medical Research Council of Australia Biomedical Career Development Award 508134 Investigating the causes of failed efferocytosis in COPD/emphysema with a view to identifying novel therapeutic targets. S Hodge $375,250.00
2008-2010 National Health and Medical Research Council of Australia Project Grant 508121      Monitoring of leukocyte cytokine /chemokine molecules to improve morbidity in lung transplant patients. PN Reynolds, MD Holmes, G Hodge, S Hodge, D Chambers. $371,604.00
2005-2007 National Health and Medical Research Council of Australia Project Grant 349337      The Role of Apoptosis and Macrophage Function in Chronic Obstructive Pulmonary Disease  P N. Reynolds, MD. Holmes, G Hodge, S Hodge       $463,400.00
2008-2011 National Health and Medical Research Council of Australia Clinical Career Development Award 508135 Relinquished for Biomedical Career Development Award.    Investigating the causes of failed efferocytosis in COPD/emphysema with a view to identifying novel therapeutic targets. Sandra  Hodge    $370,000.00
2008-2011   National Health and Medical Research Council of Australia Biomedical Career Development Award 508135 Investigating the causes of failed efferocytosis in COPD/emphysema with a view to identifying novel therapeutic targets. Sandra Hodge $370,000.00

                                                                                                               

Previous funding- non NHMRC

2016 RAH Respiratory Clinical Trials Unit Support for Transplant Research $66,931 Hodge S and Hodge G

2016 Asthma Australia Travel Award for mid-career researchers Tran H, Hodge S (supervisor) $5000

2016 RAH Clinical Project Grant. Better understanding and treating the defect in airway macrophage phagocytosis of potentially pathogenic bacteria in chronic obstructive pulmonary disease (COPD). Whittall J, Hodge S $50,000

2016 Thoracic Society of Australia and New Zealand Robert Pierce Grant-in-Aid for Indigenous Lung Health. Hodge S $15,000

2016 Research Infrastructure Block Grants (RIBG). FACSCanto II Flow Cytometer Maintenance and Calibration Hodge S, Hodge G 70,000

2016 Research Infrastructure Block Grants (RIBG) Hodge G, Hodge S $40,000

2015 RIBG Funding Hodge G, Hodge S $22,000
2015 Asthma Australia Travel Award for mid-career researchers Hodge S $5000
2014 RAH Clinical Project Grant Hodge G, Hodge S $35,000
2013-14 Lung Foundation Australia/ Boehringer Ingelheim COPD Research Fellowship   $160,000
2014 Menarini Hodge G, Hodge S $20,000
2013 Thoracic Society of Australia and New Zealand Robert Pierce Grant-in-Aid for Indigenous Lung Health. Hodge S $15,000
2013-2014   Channel 7 Children’s Research Foundation APP13688 Adaptive and innate immunity in children with bronchiectasis. Chang A, Hodge S, Yerkovich S, Pizzutto S. $75,000
2012 Royal Adelaide Hospital Clinical Research Grant. Reducing steroid resistance by targeting P-gp1 on pro-inflammatory T-cell subsets to reduce inflammation in COPD       Hodge G, Hodge S      $45,000

                                                                             

    Expand
  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2018 Principal Supervisor Role of Lc3-associated Phagocytosis in COPD and Lung Cancer Patho-genesis Doctor of Philosophy Doctorate Full Time Mr Patrick Fordjour Asare
  • Past Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2011 - 2015 Principal Supervisor Genetic and Epigenetic Characterization of the Sphingosine-1-Phosphate Signalling System in Macrophages in Chronic Obstructive Pulmonary Disease Doctor of Philosophy Doctorate Full Time Mr Jameel Barnawi
    2004 - 2008 Co-Supervisor Characterisation of Markers Associated with Systemic Inflammation in Children with Chronic Kidney Disease Doctor of Philosophy Doctorate Part Time APrf Judith Nairn
  • Other Supervision Activities

    Date Role Research Topic Location Program Supervision Type Student Load Student Name
    2021 - 2021 Principal Supervisor Neutrophil Endothelin-1 Signalling in Cystic Fibrosis - Potential Role in Development of Pulmonary Hypertension and its Therapeutic Modulation The University of Adelaide Masters of Biotechnology Master Full Time Sindhuja Nallari;
    2018 - ongoing Principal Supervisor Mechanistic and therapeutic studies of impaired phagocytic removal and xenophagic degradation of airway bacteria in COPD The University of Adelaide Doctorate Patrick Asare
    2018 - ongoing Principal Supervisor Assessing the role of SIRT-1 in airway macrophage dysfunction in COPD (and its association with the sphingosine-1-phosphate pathway) The University of Adelaide Honours Full Time Alarmelu Ram
    2018 - 2018 Principal Supervisor Investigating the capacity of azithromycin treatment to upregulate SIRT-1 expression and negate the airway macrophage dysfunction in COPD The University of Adelaide MBBS Elective Other Full Time Charles Jones
    2017 - ongoing Other Create Communicate Connect Program The University of Adelaide Create Communicate Connect Program Other n/a
    2016 - 2017 Principal Supervisor the immune molecule CD1b, and its potential role in the pathogenesis of COPD. The University of Adelaide Honours Full Time Charles Jones
    2011 - 2011 External Supervisor Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease Flinders University Honours Full Time Fabian Cordts
    2010 - 2010 Principal Supervisor Cytotoxic T-cell -mediated immune responses in patients with lung cancer and chronic obstructive pulmonary disease (COPD): implications for immune evasion by cancer cells The University of Adelaide Honours Full Time Cyd Soriano
    Expand
  • Board Memberships

    Date Role Board name Institution name Country
    2017 - ongoing Director The Thoracic Society of Australia and New Zealand Limited The Thoracic Society of Australia and New Zealand Australia
    2017 - ongoing Director Board of the Thoracic Society of Australia and New Zealand Limited
  • Committee Memberships

    Date Role Committee Institution Country
    2015 - ongoing Member CAHLN RRC Clinical Project Grant Committee
    2015 - ongoing Member RAH Research Foundation Research Infrastructure Block Grants Committee
    2015 - ongoing Chair TSANZ Cell Biology and Immunology SIG
    2015 - ongoing Chair Research Committee Awards Sub-committee, TSANZ
    2013 - ongoing Member TSANZ Research sub-committee
    2013 - ongoing Member SA Pathology/ Hanson Institute Research equipment Advisory Committee
    2013 - 2016 Member TSANZ Research sub-committee
    2012 - ongoing Member Education and Research-subcommittee Thoracic Society of ANZ
    2012 - 2016 Member NHMRC GRP
  • Memberships

    Date Role Membership Country
    2015 - ongoing Asia Pacific Society of Respirology
    2012 - ongoing International Society for Heart and Lung Transplantation
    2012 - ongoing European Respiratory Society
    2012 - ongoing American Thoracic Society
    2010 - ongoing Australian Lung Foundation
    2005 - ongoing Thoracic Society of Australia and New Zealand
  • Consulting/Advisories

    Date Institution Department Organisation Type Country
    2017 - ongoing Thoracic Society of Australia and New Zealand Australia
    2017 - ongoing Thoracic Society of Australia and New Zealand and the Lung Foundation Australia Australia
  • Offices Held

    Date Office Name Institution Country
    2017 - ongoing Deputy Treasurer The Thoracic Society of Australia and New Zealand Australia
    2017 - ongoing Finance and Risk Assessment Committee The Thoracic Society of Australia and New Zealand Australia
    2017 - ongoing Co-chair Research Committee The Thoracic Society of Australia and New Zealand Australia
  • Position: Head Chronic Lung Disease Research Lab
  • Phone: 83137080
  • Email: sandra.hodge@adelaide.edu.au
  • Campus: North Terrace
  • Building: Adelaide Health and Medical Sciences, floor 7
  • Room: WS7058.01
  • Org Unit: Adelaide Medical School

Connect With Me
External Profiles